Stock Code: 605016 Stock Abbreviation: Bailong Chuangyuan Announcement No.: 2025-066
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.
Announcement of Q3 2025 Results
The key financial data for the third quarter of 2025 contained in this announcement are preliminary and have not been audited by an accounting firm. Specific data is subject to the data disclosed in the company's third quarter report for 2025. Investors are reminded of the investment risks.
1. Key financial data and indicators for the third quarter of 2025
Unit: Ten thousand RMB
|
Project |
This reporting period |
Same period last year |
Increase/decrease rate (%) |
|
Total operating revenue |
|
82,038.74 |
18.10 |
|
Operating profit |
31,209.45 |
20,841.02 |
49.75 |
|
Total profit |
31,198.12 |
20,814.07 |
49.89 |
|
Net profit attributable to shareholders of listed companies |
|
18,259.16 |
44.93 |
|
Net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses |
26,007.56 |
17,291.11 |
50.41 |
|
Basic earnings per share (RMB) |
0.63 |
0.57 |
10.53 |
|
Weighted average return on equity (%) |
14.61 |
11.42 |
An increase of 3.19 percentage points |
|
Project |
End of this reporting period |
At the beginning of this reporting period |
Increase/decrease rate (%) |
|
Total assets |
|
201,350.48 |
28.03 |
|
Owners' equity attributable to shareholders of listed companies |
|
167,923.71 |
11.81 |
|
Share capital (10,000 shares) |
|
32,308.64 |
30.00 |
|
Net assets per share attributable to shareholders of listed companies (RMB) |
4.47 |
5.02 |
-13.99 |
Note: The beginning balance of this reporting period is the same as the end balance of the previous year as disclosed by law.
2. Operating Performance and Financial Status
2.1 Operating Performance
During the reporting period, the Company's production and operations remained normal, with domestic and international businesses operating normally, achieving steady revenue growth and rapid profit growth. In the third quarter of 2025, the Company achieved total operating revenue of RMB968,895,600, an increase of 18.10% year-on-year; net profit attributable to shareholders of the listed company was RMB264,625,700, a year-on-year increase of 44.93%; and basic earnings per share was RMB0.63, a year-on-year increase of 10.53%. This was primarily due to: 1. The Company's product mix optimization and adjustments; 2. Increased sales and revenue driven by the release of production capacity from the "30,000 tons per year soluble dietary fiber project" and the "15,000 tons per year crystalline sugar project"; and 3. The Company's 2024 equity distribution, which consisted of a 3-for-10 share bonus issued to all shareholders from the capital reserve, increased the total share capital to 420,012,320 shares.
2.2 Financial Status
As of the end of this reporting period, the Company's financial status was normal. Total assets were RMB2,577,826,200, an increase of 28.03% from the beginning of the period. Owners' equity attributable to shareholders of the listed company was RMB1,877,630,200, an increase of 11.81% from the beginning of the period. Share capital was 420,012,300 shares, an increase of 30.00% from the beginning of the period. Net assets per share attributable to shareholders of the listed company was RMB4.47, a decrease of 13.99% from the beginning of the period. This increase was primarily due to the Company's 2024 annual equity distribution, which was a 3-for-10 share bonus to all shareholders from the capital reserve, resulting in an increase in total share capital.
3. Risk Warning
The key financial data for the third quarter of 2025 contained in this announcement are preliminary and have not been audited by an accounting firm. Specific data is subject to the data disclosed in the company's third quarter report for 2025. Investors are advised to be aware of investment risks.
4. Documents for Inspection
Comparative balance sheet and income statement signed and stamped by the company's principal, the person in charge of accounting, and the head of the accounting firm.
This announcement is hereby made.
Board of Directors of Shandong Bailong Chuangyuan Biotechnology Co., Ltd.
Bailong's products as below
1.Resistant Dextrin(Soluble corn fiber), Polydextrose
2.Allulose, Isomalt, Isomaltulose, Crystalline Fructose
3.Isomalt-oligosaccharide (Organic Tapioca IMO),Xylo-oligosaccharide (XOS),Fructo-oligosaccharide(FOS),Galacto-oligosaccharide(GOS)
October 14, 2025